Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GANX Gain Therapeutics	$1.99 +5.9%	$1.69	$0.95 ▼ $3.19	$71.54M	0.1	372,770 shs	599,362 shs
INKT MiNK Therapeutics	$14.24 -3.9%	$15.41	$4.56 ▼ $76.00	$64.41M	0.33	124,068 shs	51,696 shs
RPTX Repare Therapeutics	$1.67 +0.6%	$1.52	$0.89 ▼ $4.07	$71.74M	0.93	88,788 shs	48,875 shs
SYBX Synlogic	$1.46 +0.7%	$1.40	$0.90 ▼ $1.96	$16.96M	0.52	44,934 shs	9,218 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GANX Gain Therapeutics	0.00%	+1.02%	+36.30%	+12.11%	+49.62%
INKT MiNK Therapeutics	0.00%	-4.43%	-6.07%	+104.01%	+79.14%
RPTX Repare Therapeutics	0.00%	+5.03%	+10.60%	+20.14%	-44.70%
SYBX Synlogic	0.00%	0.00%	-5.19%	+24.79%	-2.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GANX Gain Therapeutics	2.1223 of 5 stars	3.5	3.0	2.2	0.0	0.6
INKT MiNK Therapeutics	2.8388 of 5 stars	3.3	5.0	1.7	1.7	0.6
RPTX Repare Therapeutics	2.7603 of 5 stars	3.3	3.0	2.7	2.5	0.6
SYBX Synlogic	1.1232 of 5 stars	0.0	3.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GANX Gain Therapeutics	3.00	Buy	$7.80	291.96% Upside
INKT MiNK Therapeutics	2.60	Moderate Buy	$37.50	163.34% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	169.46% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SYBX, RPTX, INKT, and GANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/15/2025	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$35.00 ➝ $35.00
8/13/2025	GANX Gain Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
7/18/2025	INKT MiNK Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/15/2025	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$35.00
7/11/2025	INKT MiNK Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/3/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GANX Gain Therapeutics	$50K	1,430.81	N/A	N/A	$0.10 per share	19.90
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($5.57) per share	N/A
RPTX Repare Therapeutics	$53.48M	1.34	N/A	N/A	$2.57 per share	0.65
SYBX Synlogic	$10K	1,708.20	N/A	N/A	$1.08 per share	1.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GANX Gain Therapeutics	-$20.41M	-$0.63	N/A	N/A	N/A	N/A	-289.10%	-155.11%	11/13/2025 (Estimated)
INKT MiNK Therapeutics	-$9.51M	-$2.88	N/A	N/A	N/A	N/A	N/A	-227.24%	11/13/2025 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$2.58	N/A	N/A	N/A	N/A	-78.25%	-66.85%	11/6/2025 (Estimated)
SYBX Synlogic	-$23.36M	-$0.08	N/A	N/A	N/A	N/A	-8.09%	-5.50%	11/11/2025 (Estimated)

Latest SYBX, RPTX, INKT, and GANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INKT MiNK Therapeutics	-$0.55	-$1.06	-$0.51	-$1.06	N/A	N/A
8/12/2025	Q2 2025	GANX Gain Therapeutics	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
8/8/2025	Q2 2025	RPTX Repare Therapeutics	-$0.56	-$0.39	+$0.17	-$0.39	$2.50 million	$0.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GANX Gain Therapeutics	0.09	1.79	1.79
INKT MiNK Therapeutics	N/A	0.15	0.15
RPTX Repare Therapeutics	N/A	6.30	6.30
SYBX Synlogic	N/A	3.63	3.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GANX Gain Therapeutics	11.97%
INKT MiNK Therapeutics	2.87%
RPTX Repare Therapeutics	85.09%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
GANX Gain Therapeutics	7.18%
INKT MiNK Therapeutics	22.48%
RPTX Repare Therapeutics	11.50%
SYBX Synlogic	3.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GANX Gain Therapeutics	20	35.95 million	33.37 million	Optionable
INKT MiNK Therapeutics	30	4.52 million	3.51 million	No Data
RPTX Repare Therapeutics	180	42.96 million	38.02 million	Optionable
SYBX Synlogic	80	11.70 million	11.35 million	Optionable

SYBX, RPTX, INKT, and GANX Headlines

Recent News About These Companies

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

Synlogic Inc.

July 21, 2024 | wsj.com

Synlogic Inc SYBX

July 21, 2024 | morningstar.comM

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

May 23, 2024 | investorplace.com

Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties

May 16, 2024 | markets.businessinsider.com

SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | investorplace.com

Synlogic, Inc.: Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | finanznachrichten.de

Synlogic Flat on Q1 Numbers

May 14, 2024 | baystreet.ca

Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX, RPTX, INKT, and GANX Company Descriptions

Gain Therapeutics NASDAQ:GANX

$1.99 +0.11 (+5.85%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.01 +0.02 (+1.21%)

As of 08/29/2025 08:00 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

MiNK Therapeutics NASDAQ:INKT

$14.24 -0.58 (-3.91%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$14.70 +0.46 (+3.23%)

As of 08/29/2025 07:44 PM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Repare Therapeutics NASDAQ:RPTX

$1.67 +0.01 (+0.60%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.65 -0.02 (-1.20%)

As of 08/29/2025 04:04 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Synlogic NASDAQ:SYBX

$1.47 +0.02 (+1.45%)

As of 08/29/2025 04:00 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time